^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Adenocarcinoma, large cell, NSCLC NOS (PS 0-1)…Continuation maintenance...Atezolizumab
Secondary therapy:
carboplatin + paclitaxel
Source:
Excerpt:
Adenocarcinoma, large cell, NSCLC NOS…Other recommended…Atezolizumab/carboplatin/albumin-bound paclitaxel
Secondary therapy:
carboplatin + albumin-bound paclitaxel
Source:
Title:
Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
Published date:
11/14/2023
Excerpt:
Roche...announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC, or under the skin) Tecentriq® (atezolizumab)...The CHMP’s positive opinion is based on pivotal data from the Phase IB/III IMscin001 study, which showed comparable levels of Tecentriq in the blood, when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation.
Source:
Title:
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
Published date:
07/06/2023
Excerpt:
First-line treatment with atezolizumab monotherapy was associated with improved overall survival, a doubling of the 2-year survival rate, maintenance of quality of life, and a favourable safety profile compared with single-agent chemotherapy. These data support atezolizumab monotherapy as a potential first-line treatment option for patients with advanced NSCLC who are ineligible for platinum-based chemotherapy.
DOI:
10.1016/S0140-6736(23)00774-2
Trial ID:
